Summary
Regulatory T (Treg) cells play a key role in dampening excessive immune activation. However, antiretroviral therapy (ART) -naive HIV-1 infection maintains the immune system in a sustained state of activation that could alter both Treg cell surface markers and functions. As Treg cell surface markers are directly linked to their functions the overall objective of this study was to determine how ART-naive HIV infection affects the phenotypic properties of Treg cells. Our data showed that in ART-naive HIV- 1 ) cells. Whereas effector and effector memory Treg cells showed enhanced expression of CD39 (P < 0Á05), CD73 (P < 0Á001), HLA-DR and CD38 (P < 0Á001); naive and central memory Treg cells showed a significant reduction in the expression of these markers. Overall Treg cell frequencies within total CD4 + T cells correlated positively with plasmatic HIV-1 viral load. As increased viral load is associated with augmented CD4 + T-cell destruction; this could suggest a resistance of peripheral
Introduction
Chronic infection with HIV-1 maintains the immune system in a sustained state of activation ultimately culminating in CD4 + T-cell depletion and immune suppression. 2,3 Such Treg cell dysfunctions have been linked to several diseases including allergy, autoimmunity, cancers and early graft rejection. 4 Regulatory T cells are expected in steady states to dampen excessive immune activation, thereby limiting tissue damage and preventing immunopathologies. 3 However, in the context of a challenging persistent infection such as HIV, Treg 
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cell function in vivo is probably limited as a result of either direct infection of Treg cells by HIV 5 or poor interaction of Treg cells with other immune cells like dendritic cells in the destroyed tissue micro-environment. 6 Nevertheless, previous studies have demonstrated the beneficial effect of Treg cells in reducing HIV-1-associated immune activation and inflammation. [7] [8] [9] Treg cells have also been shown to suppress both HIV-specific T-cell proliferation and cytokine production. This on the one hand can result in a reduction of the available target cells for HIV replication, thereby limiting disease progression. On the other hand, the suppression of critical virus-specific immune responses could be deleterious to the individual, especially with respect to unchecked viral expansion and inflammation. [10] [11] [12] The phenotype of Treg cells in vivo is vital to their function, so we employ multiparametric flow cytometry to assess the phenotype of Treg cells freshly purified by magnetic sorting from peripheral blood mononuclear cells (PBMCs) obtained from ART-naive HIV-infected participants from the CIRCB AFRODEC cohort. Our hypothesis being that Treg cell phenotype in the context of ART-naive HIV infection when associated with viral load and helper CD4 T-cell count could be used in predicting the role of Treg cells in the challenging environment created by HIV infection.
The need to purify Treg cells during this study arises because they represent a small fraction of CD4 + T cells (5-10%) in steady state, which are further depleted during ART-naive HIV-1 infection, making it difficult to obtain an adequate amount for in vitro studies with bulk PBMCs. As Treg cells constitutively express CD25, the interleukin-2 receptor a chain component, 13 FoxP3, the forkhead box P3 transcription factor protein, 14 and low levels of CD127, the interleukin-7 receptor a-chain, 15 we decided to use these markers to track Treg cells during multiparametric FACS analysis.
The purity of the magnetically sorted Treg cells ranged between 90 and 95% for both PBMCs from ART-naive HIVinfected and PBMCs from sero-negative participants. As CD127 has been shown to be inversely correlated with FoxP3, 16 we assessed whether the combination of CD127 lo CD25 + can provide a good alternative to FoxP3 for tracking Treg cells of ART-naive HIV-infected individuals. We demonstrated that FoxP3 + expression of both ART-naive HIV-positive and -negative people correlated positively with the numbers of CD127 lo CD25 + thereby implying that these markers could be used for tracking their Treg cells.
Our data showed that in ART-naive HIV- ) phenotype. Both effector and effector memory Treg cells showed significant increases in CD39 (P < 0Á05), CD73 (P < 0Á001), HLA-DR and CD38 (P < 0Á001) expression, which have been associated with immunomodulatory suppressive functions of Treg cells. [17] [18] [19] Overall, the total number of Treg cells correlated positively with the helper CD4 + T-cell count and inversely with plasmatic HIV viral load. However, when Treg cell frequencies were considered they correlated inversely with CD4 + T-cell count and positively with plasmatic HIV viral load. These results allowed us to categorize ART-naive HIV-1-infected individuals into two categories. First, those with low Treg cell frequencies (helper CD4 T-cell count > 350 cells/mm 3 ) with comparatively less plasmatic viral load, and second, people displaying high Treg cell frequencies (helper CD4 + T-cell count < 350 cells/mm 3 ) with severe immune suppression and elevated viral load. This implies that the success of immunotherapeutic strategies targeting Treg cells in the context of ARTnaive HIV infection could be assessed by considering Treg phenotypes and frequencies. These results are highly relevant because they provide a framework for defining the Treg cell phenotypes and frequencies that are desirable during targeted immotherapeutic strategies aimed at restoring Treg cell function in HIV infection.
Materials and methods

Study populations
Thirty-one ART-naive HIV-1-infected participants (22 female and 9 male) were recruited from the CIRCB AFRODEC cohort. Seventeen HIV-negative participants (12 female and 5 male) were also recruited as controls. In addition to people who did not provide consent, participants who had been diagnosed with hepatitis B virus, hepatitis C virus, Dengue virus, Mycobacterium tuberculosis, or malaria were excluded from the study. Absolute numbers of helper CD4 + T cells for both HIV + and HIV À participants were determined in fresh whole blood by BD multitest CD3/CD8/CD45/CD4 and TruCount tubes (BD Biosciences, San Jose, USA) according to the manufacturer's instructions. Plasmatic HIV-1 viral load was determined on the m2000rt machine using the Abbott RealTime HIV-1 Assay protocol.
Cell preparation
Isolation of PBMCs. The PBMCs were isolated from whole blood within 2-4 hrs of sampling by density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare BioSciences, Uppsala, Sweden + T cells were negatively selected following incubation with streptavidin particles for 30 min at room temperature. They were then transferred to a BD Falcon tube, placed within the magnetic field of the BD IMagnet (Cat. No. 552311) and depleted of labelled cells. This negative selection was repeated twice to increase the yield of the enriched fraction. Second, the CD25 + Treg cells were isolated from the twice-enriched fraction by positive selection using the BD IMagnet after incubation with Anti-APC particles for 30 min at room temperature. To increase its purity, positive selection was repeated three times.
Antibodies
The monoclonal antibodies used for surface staining in this study included Brilliant Violet (BV)-421-labelled anti-CD127 (clone 9HIL-7R-M21), BV-650 labelled anti-CD39 (clone TU66), BV605-conjugated anti-CD62L (clone DREG-56) and Fixable Viability stain 510, all purchased from BD Biosciences. Alexa-Fluor 700 labelled anti-HLA-DR (clone LN3), peridinin-chlorophyll proteineFluor 710 conjugated anti-CCR7 (clone 3D12) and FITC-labelled anti-CD27 (clone LG.7F9) were obtained from eBiosciences (San Diego, CA, USA). Phycoerythrin (PE) -conjugated anti-CD25, PE-cyanine 7 (PE-Cy7) -labeled anti-CD73 (clone AD2), PE-Cy5-labelled anti-CD45RA (clone HI100) and allophycocyanin (APC) -labelled anti-CD38 were provided by BD Pharmingen (San Diego, CA, USA). APC Vio770-conjugated anti-CD3 (clone BW 264/56) and PE-Texas Red-conjugated anti-CD4 were obtained from Miltenyi Biotec and Beckman Coulter (Brea, Fullerton, CA, USA) respectively.
PE-Cy7-labelled anti-FoxP3 (clone PCH101) was supplied by eBioscience and used for intracellular staining.
Optimal concentration was determined for each antibody by testing serial dilutions starting with the concentration recommended by the manufacturers.
Phenotypic characterization of Treg cells
Bulk PBMCs or sorted Treg cells were first incubated for 20 min at 4°in the dark, with 1% FcR blocking solution (Miltenyi Biotec) diluted in FACS buffer and then stained on the surface with a cocktail of fluorochrome-labelled antibodies to CD3, CD4, CD25, CD127, HLA-DR, CD38, CD45RA, CD27, CD39, CD73, CCR7, CD62L, CCR7, CD27 and Live/Dead. After incubation for 20 min at 4°i n the dark, the cells were washed with FACS buffer, and then fixed and permeabilized with a FoxP3 fixation/permeabilization buffer (eBioscience) at 4°for 45 min in the dark. Cells were stained intracellularly with anti-FoxP3 for 30 min at 4°protected from the light. Two rounds of cell washes with FoxP3 permeabilization buffer (eBioscience) were employed before and after intracellular labelling. Next, the cells were re-suspended in FACS buffer and acquired on BD Fortessa X-20 cytometer using BD FACS DIVA software (BD Biosciences, San Jose, CA, USA). One thousand events were collected within a gate set on CD4 + CD127 lo cells.
Statistical analysis
All flow cytometric data were analysed using FLOWJO software (Tree Star, Ashland , OR, USA) version 9Á8Á5 and statistical analyses were performed using GRAPHPAD PRISM version 5Á0 (Graphpad, San Diego, CA, USA). The data were shown as median (25-75th percentile). Comparisons of medians among two groups were performed using the Mann-Whitney U-test. A Kruskal-Wallis test with Dunn's multiple comparisons post-test was used to test for differences between more than two groups. Correlations were made with Spearman test and P-values < 0Á05 were considered to be statistically significant.
Ethical considerations
This study received ethical approval from the Cameroon National Ethics Committee for Human Health Research.
(Reference number No. 2015/03/569/CE/CNERSH/SP). All participants provided written informed consent. Data were processed using specific identifiers for privacy and confidentiality purposes. Clinical data generated during the course of this study were provided free of charge to all participants. 21 They were analysed using the gating strategy shown in Fig. 1a . To determine their total number in ART-naive HIV-infected participants, we did a FoxP3 staining either in bulk PBMCs or in magnetically sorted Treg cells. As shown in Fig. 1(b,c) Fig. 1b,c) . Next, we assessed the relationship between the surface expression of a combination of CD25 and CD127 and the transcription factor, FoxP3 which is the signature marker of Treg cells.
Results
Study population
14 To achieve this, we plotted the number of CD4 + T cells expressing a combination of CD25 + and CD127 lo against the number of cells positive for FoxP3. Using Spearman correlation analysis, we could demonstrate a positive correlation between CD25 + CD127 lo and FoxP3 expression in all the categories listed above. This correlation was determined for PBMCs (r = 0Á94; P < 0Á0001; Fig. 1d ), 3 (n/%) 1(3) 4 (13) Median viral load (Log 10 copies/ml) NA NA 4Á66 (3Á31-5Á63) 3Á98 (2Á56-5Á04) *P < 0Á05; **P < 0Á001; ***P < 0Á0001; NA, not applicable; IQR, interquartile range; n = number of participants. A total of 31 HIV-positive participants were recruited for this study with 71% being female and the rest (29%) male. The median ages were 37 (32Á50-42Á50) years for women and 45 (37Á50-46) years for men. Seventeen HIV-negative participants were recruited as controls. Relative to the controls, there was a significant reduction (P < 0Á001 for men and P < 0Á0001 for women) of helper CD4 counts as a consequence of antiretroviral naive HIV-1 infection. Whereas a most participants (55%) showed no significant immune suppression (CD4 > 500 cells/mm 3 partially purified Treg cells (r = 0Á86; P < 0Á0001; Fig. 1e ) and fully purified Treg cells (r = 0Á71; P < 0Á0002; Fig. 1f ).
Due to this strong correlation we therefore selected CD4 + CD25 + CD127 lo expression for subsequent tracking of Treg cell phenotypes.
Relationship between helper CD4
+ T-cell count and Treg cells + T-cell counts decreased (Fig. 2b) . The highest Treg cell frequencies were observed in samples from ART-naive HIV-1-infected participants with helper CD4 + T-cell counts < 350 cells/mm 3 (5%; 4Á44-6Á89) comparative to samples with helper CD4 + T-cell counts between 350 and 499 cells/mm 3 (1Á84%; 1Á17-3Á33; P < 0Á05) and to those with helper CD4 + T-cell counts ≥500 cells/mm 3 (1Á48%; 1Á23-2Á3; P < 0,001). In addition, helper CD4 + T-cell counts correlated positively with total Treg cell numbers (r = 0Á60, P = 0Á0005; Fig. 2c ) and negatively with Treg cell frequencies (r = À0Á58, P = 0Á0009; Fig. 2d ) using the Spearman test. 
HIV infection modulates Treg cell frequencies and numbers
We further evaluated the relationship between plasmatic HIV-1 viral loads and the total number of Treg cells on the one hand and the proportions of Treg cells on the other. Our results indicated that plasmatic HIV-1 viral loads correlated negatively with the total number of Treg cells (r = À0Á51; P = 0Á011; Fig. 3a ,c) and positively with Treg cell frequencies (r = 0Á55; P = 0Á007; Fig. 3b,d ).
Our data indicate that the Treg cell frequencies within total CD4 + T cells could be relevant in predicting the degree of CD4 + T-cell depletion in ART-naive HIV-infected people.
Identification of Treg cell subsets in ART-naive HIV infection using CD45RA, CD27, CD62L and CCR7 cell surface markers
Using multi-parametric FACS analysis, Treg cells from peripheral blood of study participants displayed a heterogeneous expression profile relative to CD45RA, CD27, CD62L and CCR7 cell surface markers (Fig. 4b,c) (Fig. 4a) . As shown in Fig. 4(b,c) , whereas uninfected people displayed predominantly naive (P < 0Á001) and central memory (P < 0Á05) phenotypes, HIV-infected participants showed significantly elevated numbers of effector (P < 0Á001) and effector memory (P < 0Á05) Treg cell subsets.
ART-naive HIV-infection reduces CD39 and CD73 expression in naive and central memory Treg cells
CD39, a member of the ectonucleoside triphosphate diphosphohydrolases, is strongly associated with suppressive immunomodulatory functions by hydrolysing the pro-inflammatory ATP to AMP, which in turn is converted to adenosine by the ecto-5 0 -nucleotidase CD73. 18 Here we showed a significant increase in the number of effector and effector memory 3 ; P < 0Á001, respectively, for effector and effector memory Treg cells]. In contrast, naive and central memory Treg cells from uninfected people displayed increased expression of both CD39 and CD73 (P < 0Á0001; Fig. 5f ). The same tendency was observed when the expression was analysed in mean fluorescence intensity (MFI). The MFI of both CD39 and CD73 are shown in the Supplementary material ( Figure S2 ). As Treg cells in seronegative participants are dominated by naive and central memory phenotypes, the reduction in the expression of these markers in ART-naive HIVinfected people could be relevant in Treg cell function impairment.
Expression of HLA-DR and CD38 on Treg cell subsets
The activation status of Treg cells from ART-naive HIVinfected participants was assessed following HLA-DR and CD38 expression analysis in different Treg cell subsets (Fig. 6) . In HIV-infected participants, HLA-DR expression was significantly higher in effector [28 (19Á75- 
Discussion
The present study was designed to determine phenotypic features of Treg cells in the context of ART-naive HIV infection for possible application in optimizing Treg cell targeted immunotherapeutic strategies. The choice of ART-naive HIV infection becomes expedient because it represents the most appropriate situation where the interaction between HIV and the immune system can be explored without external confounding factors. The CIRCB AFRODEC cohort of ART-naive HIV-infected people has been in existence since 2011, permitting us to go back in time and correlate virological and immunological parameters with purified Treg cell phenotypes. To date CD4, CD127, CD25 and FoxP3 represent the most used markers for Treg cell identification. 15, 21 Figure 3 . HIV infection modulates regulatory T (Treg) cell frequencies and numbers. HIV-infected participants were divided into three groups according to their plasmatic HIV viral loads [VL< 3 Log copies/ml (n = 8); 3-4 (n = 8); > 4 (n = 12)]. The total number of Treg cells decreased when the plasmatic HIV viral load increased (a), whereas an inverse tendency was observed when Treg cell frequencies were considered (b) although the differences were not significant using Kruskal-Wallis test. However, plasmatic HIV viral load correlated negatively with total Treg cell numbers (r = À0Á51; P = 0Á011; c) and positively with Treg cell frequencies (r = 0Á55; P = 0Á007; d) using Spearman test. tively. Whereas seronegative people displayed predominantly naive (P < 0Á05) and central memory (P < 0Á001) phenotypes, antiretroviral therapy-naive HIV-infected participants showed significantly elevated numbers of effector (P < 0Á001) and effector memory (P < 0Á05) Treg cell subsets. Bars represent the median and Mann-Whitney U-test was used to compare each subset between HIV-infected and uninfected controls. *P<0Á05; **P<0Á001. , respectively. The differences between HIV + and HIV -participants were calculated using Mann-Whitney U-test. Effector and effector memory Treg cells from antiretroviral therapy-naive HIV-infected participants showed significant increase in CD39 (P < 0Á05) and CD73 (P < 0Á001) expression. In contrast, these markers were highly expressed instead on naive (P < 0Á05 and P < 0Á0001 respectively for CD39 and CD73) and central memory (P < 0Á05 for CD73) Treg cells from uninfected individuals. A similar trend was observed for the combined expression of both CD39 and CD73. *P <0Á05, **P <0Á001, ****P <0Á0001. correlation between CD127 lo CD25 + and FoxP3 + was established either through the staining of bulk PBMCs (r = 0Á94; P < 0Á0001; Fig. 1d ), partially purified (r = 0Á86; P < 0Á0001; Fig. 1e ) or fully purified Treg cells (r = 0Á71; P = 0Á0002; Fig. 1f) . 16, 23 To understand the nature of Treg cells in freshly purified PBMCs we assessed the relationship between both total Treg cell numbers and Treg cell frequencies (i.e. Treg cell proportion in total CD4 + T cells) with respect to helper CD4 + T-cell count and HIV plasmatic viral load as markers of disease progression. As reported in previous studies 10, 15, 21, 24, 25 there was a proportionate reduction of Treg cell numbers vis-a-vis helper CD4 + T-cell counts (r = 0Á60, P = 0Á0005). In contrast to plasmatic HIV load, which increased inversely with Treg cell numbers, here significantly (P < 0Á05) + T cells have previously been demonstrated to express chemokine receptors CCR5 and CXCR4, which are required for HIV-1 entry into host cells and are therefore potential targets for HIV-1 infection and destruction. 5, [26] [27] [28] Another probable scenario may be the recruitment of HIV-specific Treg cells to sites of HIV infection and replication, such as the mucosa and lymph nodes. 3, 17 However, when considered in terms of Treg cell frequencies T-cell subsets. In contrast to our data Gaardbo et al., reported similar Treg cell numbers and frequencies in HIV-infected participants and healthy controls. 30 The lack of difference between their study groups was probably due to similarity in their helper CD4 + T-cell counts, which were all within the normal range (> 500 cells/ mm 3 ). Hence, whereas their study population was mainly people with no detectable immunosuppression by CDC categorization, the differences in Treg cell frequencies observed by our group were mainly in people with advanced immunosuppression. Increased in Treg cell frequencies have generally been reported in advanced immunosuppression which in essence could be an indication of Treg cell-mediated suppression against CD4 + T cells. 19 This is in contrast to a reduction in Treg cell numbers, which probably suggest a decrease in their suppression capacity on other immune cells. This assertion is supported by the fact that efficacious ART is generally accompanied by a progressive decrease of Treg cell frequencies to normal levels 17, [31] [32] [33] [34] and a proportionate increase of Treg cell counts with CD4 + T-cell counts. 
CD27
-CCR7 -CD62L -) phenotypes. Whereas uninfected people displayed predominantly naive (P < 0Á001) and central memory (P < 0Á05) phenotypes, HIV-infected participants showed significantly elevated levels of effector (P < 0Á001) and effector memory (P < 0Á05) Treg cell subsets. To discriminate Treg cell subsets other groups have used CD45RA and CD27 expression levels. 24, 36 One major limitation of this strategy is that without taking into consideration the chemokine receptor CCR7 and the L-selectin receptor CD62L which are critical for T-cell homing into lymphoid tissues; it is impossible to clearly delineate the various Treg cell subsets. By including CCR7 and CD62L for example we were able to extend the surface markers used for delineating the four groups listed above to four as against just CD45RA and CD27 previously reported by the groups mentioned above. By so doing we could also delineate certain populations (up to 16 Treg cell subsets, see Fig. 4b,c) , which could be relevant in appreciating Treg cell phenotypes.
Following an in-depth analysis of the levels of CD39, CD73, HLA-DR and CD38 on the aforementioned four Treg cell subsets we found that effector and effector memory Treg cells in ART-naive HIV-infected participants expressed increased levels of CD39, CD73, HLA-DR and CD38. These markers have been associated with disease progression or immune activation 17, 37 and have also been shown to be involved in the suppression of HIV-specific responses and/or in Treg cell survival in the inflammatory environment created by HIV infection. 15, 19 ART-naive HIV infection drives persistent immune activation, which is directly linked with CD4 + T-cell depletion and disease progression. 38, 39 In this context the role of Treg cells in limiting HIV-1-mediated persistent immune activation is conflicting because by limiting immune activation they also invariably would inhibit HIV-1-specific immune responses. Nevertheless, low immune activation has been associated with slower disease progression 40 but the general consensus remains that sustained immune activation accelerates disease progression irrespective of viral load. 39 On the contrary Gaardbo et al., recently suggested increased activation of Treg cells to be relevant in preserving CD4 + T cells in long-term non-progressors and elite controllers. This is probably true in circumstances where there is no significant immunosuppression. However, the differences observed between Treg cell activation in elite controllers, longterm non-progressors and viral controllers may be because viral control is a transitory state. Viral controllers might ultimately become either long-term nonprogressors or progressors following prolonged interaction with the immune system.
The functional characterization of the Treg cells is in progress.
In summary our work lays the foundation for an indepth analysis of Treg cells in ART-naive HIV infection and could provide a framework for designing immunotherapeutic strategies to improve HIV infection prognosis by targeted modulation of Treg cell phenotypes and functions. Specifically, Treg cells are known to inhibit HIV-specific immune responses, so when immunotherapeutic strategies are aimed at decreasing Treg cell frequencies, this could result in a reduction in their immunosuppressive functions. 
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Additional Supporting Information may be found in the online version of this article: Figure S1 Tracking FoxP3-expressing cells using a combination of CD25 + CD127 lo markers in either magnetically sorted regulatory Tcells or bulk peripheral blood mononuclear cells. Figure S2 Antiretroviral therapy-naive HIV infection increases CD39 and CD73 expression in effector and effector memory regulatory T cells. Figure S3 Antiretroviral therapy-naive HIV infection increases activation of effector and effector memory regulatory T cells.
